ImpediMed Limited

ImpediMed is an Australian medical technology company that designs and manufactures medical devices employing bioimpedance spectroscopy (BIS) technology for the non-invasive clinical assessment and monitoring of fluid status and tissue composition in patients. Headquartered in Brisbane, it is an Australian stock exchange listed company with operations in the United States, Europe, and Australia. Its stated mission is to improve long-term patient outcomes by forging new standards of care, and its vision is to revolutionize care with fluid and body composition analytics through clinically validated, secure platform technology. The company's flagship offering is the SOZO Digital Health Platform, which it describes as the only FDA-cleared BIS technology that non-invasively measures fluid status and tissue composition in healthy and unhealthy patient populations. By measuring 256 frequencies in a single, rapid scan, BIS separates intra- and extracellular fluid to produce an accurate whole-body composition profile. A 30-second test delivers immediate results, enabling clinicians to detect disease progression early, monitor treatment, and educate patients. ImpediMed directs its primary efforts toward addressing secondary lymphedema, with a particular focus on breast cancer-related lymphedema (BCRL). Its SOZO applications include L-Dex Analysis for lymphedema, BodyComp Analysis for body composition, Segmental BodyComp Analysis for arm and leg composition, and HF-Dex Analysis for heart failure fluid assessment. The platform is positioned for use across cancer survivorship, wellness and longevity, medical weight management, and heart health management. The company markets its products to healthcare professionals, who use them to detect, assess, monitor, and manage certain diseases. ImpediMed emphasizes values of being customer-centric, excellence, integrity, and accountability, and it maintains a leadership team and newsroom through its corporate website.

ImpediMed is an Australian medical technology company headquartered in Brisbane. It designs and manufactures medical devices that employ bioimpedance spectroscopy (BIS) technology for the non-invasive clinical assessment and monitoring of fluid status and tissue composition in patients. The company is listed on the Australian stock exchange and operates in the United States, Europe, and Australia. ImpediMed has consistently directed its primary innovation efforts toward addressing the specific challenges and devastating burden of secondary lymphedema, with a focus on breast cancer-related lymphedema (BCRL). Its technology measures 256 frequencies in a single, rapid scan, separating intra- and extracellular fluid to produce an accurate whole-body composition profile. The company's flagship product is the SOZO Digital Health Platform, which it describes as the only FDA-cleared BIS technology that non-invasively measures fluid status and tissue composition in healthy and unhealthy patient populations. SOZO delivers actionable data at the point of care, enabling informed treatment, recovery, and clinical decision-making. The platform includes applications such as L-Dex Analysis for lymphedema, BodyComp Analysis for body composition, Segmental BodyComp Analysis for arm and leg composition, and HF-Dex Analysis for heart failure fluid assessment. ImpediMed markets its products to healthcare professionals for use in cancer survivorship, wellness and longevity, medical weight management, and heart health management. The company states its mission is to improve long-term patient outcomes by forging new standards of care, and its vision is to revolutionize care with fluid and body composition analytics through clinically validated, secure platform technology.

Leading global medical technology company focused on bioimpedance spectroscopy for non-invasive fluid status and tissue composition assessment, with a primary focus on secondary lymphedema and breast cancer-related lymphedema.

• SOZO Digital Health Platform

  FDA-cleared BIS technology that non-invasively measures fluid status and tissue composition in healthy and unhealthy patient populations, delivering results in 30 seconds.

• SOZO Pro

  Clinical decision support at the point of care, powered by BIS, FDA-cleared for use in healthy and unhealthy populations and for patients with pacemakers and implantable cardiac devices (ICDs).

• L-Dex Analysis

  Point-of-care lymphedema assessment for early detection at a subclinical stage.

• BodyComp Analysis

  Comprehensive point-of-care body composition analysis tracking fluid volumes and tissue.

• Segmental BodyComp Analysis

  Advanced point-of-care segmental analysis of arm and leg composition.

• HF-Dex Analysis

  Point-of-care heart failure fluid assessment.

1. 1Medical Bioimpedance Spectroscopy (BIS) Devices | ImpediMedimpedimed.com
2. 2About ImpediMed | ImpediMedimpedimed.com
3. 3Products | ImpediMedimpedimed.com
4. 4SOZO® Digital Health Platform | ImpediMedimpedimed.com
5. 5Impedimed (Australia) - Wikidatawikidata.org